As of today (2024-04-24), bluebird bio's share price is $0.9706.
bluebird bio's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $-2.83. Hence, bluebird bio's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for bluebird bio's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 12 years, bluebird bio's highest Price-to-Free-Cash-Flow Ratio was 7.57. The lowest was 7.41. And the median was 7.49.
BLUE's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 26.20% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 7.70% per year.
During the past 12 years, bluebird bio's highest 3-Year average Free Cash Flow per Share Growth Rate was 26.20% per year. The lowest was -67.00% per year. And the median was -34.65% per year.
bluebird bio Price-to-Free-Cash-Flow Historical Data
The historical data trend for bluebird bio's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, bluebird bio's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
bluebird bio Price-to-Free-Cash-Flow Distribution
For the Biotechnology industry and Healthcare sector, bluebird bio's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where bluebird bio's Price-to-Free-Cash-Flow falls into.
bluebird bio Price-to-Free-Cash-Flow Calculation
bluebird bio's Price-to-Free-Cash-Flow ratio for today is calculated as
bluebird bio's Share Price of today is $0.9706.
bluebird bio's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.83.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
bluebird bio (NAS:BLUE) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
bluebird bio Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of bluebird bio's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BLUE has been successfully added to your 